Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer

被引：0
|
作者：
Roche, H.
Penault-Llorca, F.
Berton, Rigaud D.
Tubiana, Mathieu N.
Ferrero, J. M.
Coudert, B.
Mousseau, M.
Monnier, A.
Orfuevre, H.
Audhuy, B.
Rotarski, M.
Homokos, H.
Fumoleau, P.
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Jean Perrin, Clermont Ferrand, France
[3] Ctr Rene Gauducheau, St Herblain, France
[4] Hop Dupuytren, Limoges, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] Ctr Georges Francois Leclerc, Dijon, France
[7] CHU Grenoble, La Tronche, France
[8] CH Montbeliard, Montbeliard, France
[9] CH Fleyriat, Bourg En Bresse, France
[10] Hop Louis Pasteur, Colmar, France
[11] Ctr Oncol Du Pays Basque, Bayonne, France
[12] Roche Neuilly, Neuilly Sur Seine, France
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [1] Updated safety findings from a randomized phase II trial of capecitabine plus epirubicin plus cyclophosphamide (CEX) vs. 5-FU plus epirubicin plus cyclophosphamide (FEC) as neoadjuvant therapy in patients (pts) with operable breast cancer (BC)
    Roche, Henri
    Deporte, Regine
    Berton-Rigaud, Dominique
    Coudert, Bruno
    Tubiana-Mathieu, Nicole
    Ferrero, Jean Marc
    Orfeuvre, Hubert
    Audhuy, Bruno
    Dalenc, Florence
    Fumoleau, Pierre
    ANNALS OF ONCOLOGY, 2006, 17 : 99 - 99
  • [2] Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU + epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
    Berton-Rigaud, D.
    Roche, H.
    Penault-Llorca, F.
    Tubiana-Mathieu, N.
    Ferrero, J.
    Coudert, B.
    Milano, G. A.
    Mousseau, M.
    Homokos, H.
    Fumoleau, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Pharmacokinetic and pharmacodynamic analysis of cyclophosphamide, epirubicin and capecitabine vs 5-FU, epirubicin and cyclophosphamide as neoadjuvant therapy in breast cancer patients
    Milano, G.
    Deporte, R.
    Renee, N.
    Etienne-Grimaldi, M-C
    Berton, Rigaud D.
    Ferrero, J-M
    Dalenc, F.
    Piutti, M.
    Homokos, H.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S228 - S228
  • [4] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
    Bonneterre, J
    Dieras, V
    Tubiana-Hulin, M
    Bougnoux, P
    Bonneterre, ME
    Delozier, T
    Mayer, F
    Culine, S
    Dohoulou, N
    Bendahmane, B
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1466 - 1471
  • [5] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
    J Bonneterre
    V Dieras
    M Tubiana-Hulin
    P Bougnoux
    M-E Bonneterre
    T Delozier
    F Mayer
    S Culine
    N Dohoulou
    B Bendahmane
    British Journal of Cancer, 2004, 91 : 1466 - 1471
  • [6] Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel plus cyclophosphamide plus capecitabine followed by 5-fluorouracil plus epirubicin plus cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study)
    Higaki, Kenji
    Masuda, Norikazu
    Takano, Toshimi
    Matsunami, Nobuki
    Morimoto, Takashi
    Ohtani, Shoichiro
    Mizutani, Makiko
    Miyamoto, Takeshi
    Kuroi, Katsumasa
    Ohno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A randomised clinical trial of primary chemotherapy (PC) with taxol plus epirubicin (TE) -: V.: 5-FU plus epirubicin plus cyclophosphamide (FEC) in stage IIIA breast cancer:: A preliminary report
    Malamos, N
    Papadiamantis, I
    Andonopoulos, M
    Tsikkinis, A
    Kosmas, H
    Pallis, L
    Kouri, E
    Sfikas, K
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S14 - S15
  • [8] A phase II trial of capecitabine and docetaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with breast cancer
    Jinno, H.
    Ikeda, T.
    Mukai, M.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study
    Gardin, G
    Barone, C
    Nascimben, O
    Ianniello, G
    Sturba, F
    Contu, A
    Pronzato, P
    Rosso, R
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 176 - 177
  • [10] Phase II randomized trial of docetaxel (D) monotherapy vs epirubicin plus docetaxel (ED) as neoadjuvant treatment of operable breast cancer (BC).
    Bougnoux, P
    Combe, M
    Goudier, MJ
    Facchini, T
    Lotz, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 27S - 27S
12345